284 related articles for article (PubMed ID: 33554352)
1. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
3. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
[TBL] [Abstract][Full Text] [Related]
4. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440
[TBL] [Abstract][Full Text] [Related]
6. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
[TBL] [Abstract][Full Text] [Related]
7. Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors.
Alesawy MS; Al-Karmalawy AA; Elkaeed EB; Alswah M; Belal A; Taghour MS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000237. PubMed ID: 33226150
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
[TBL] [Abstract][Full Text] [Related]
9. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
Khalifa MM; Al-Karmalawy AA; Elkaeed EB; Nafie MS; Tantawy MA; Eissa IH; Mahdy HA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):299-314. PubMed ID: 34894955
[TBL] [Abstract][Full Text] [Related]
10. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
11. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A
Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884
[TBL] [Abstract][Full Text] [Related]
12. Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies.
Abulkhair HS; Turky A; Ghiaty A; Ahmed HEA; Bayoumi AH
Bioorg Chem; 2020 Jul; 100():103899. PubMed ID: 32454390
[TBL] [Abstract][Full Text] [Related]
13. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of thiadiazolo-carboxamide bridged β-carboline-indole hybrids: DNA intercalative topo-IIα inhibition with promising antiproliferative activity.
Tokala R; Sana S; Lakshmi UJ; Sankarana P; Sigalapalli DK; Gadewal N; Kode J; Shankaraiah N
Bioorg Chem; 2020 Dec; 105():104357. PubMed ID: 33091673
[TBL] [Abstract][Full Text] [Related]
15. Design and novel synthetic approach supported with molecular docking and biological evidence for naphthoquinone-hydrazinotriazolothiadiazine analogs as potential anticancer inhibiting topoisomerase-IIB.
Mohamady S; Gibriel AA; Ahmed MS; Hendy MS; Naguib BH
Bioorg Chem; 2020 Mar; 96():103641. PubMed ID: 32032844
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects.
Turky A; Bayoumi AH; Ghiaty A; El-Azab AS; A-M Abdel-Aziz A; Abulkhair HS
Bioorg Chem; 2020 Aug; 101():104019. PubMed ID: 32615465
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
18. Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations.
Elwan A; Sakr H; El-Helby AA; El-Morsy A; Abdelgawad MA; Ghoneim MM; El-Sherbiny M; El-Adl K
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1556-1567. PubMed ID: 35635148
[TBL] [Abstract][Full Text] [Related]
19. Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II.
El-Metwally SA; Khalil AK; El-Sayed WM
Bioorg Chem; 2020 Jan; 94():103492. PubMed ID: 31864673
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
